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Introduction: Posterior reversible encephalopathy syndrome is an extremely rare radiological diagnosis that has
not been reported previously in association with acute liver failure.
Case presentation: A 6-year-old Sri Lankan girl developed acute liver failure with severe hepatic encephalopathy
due to sodium valproate. She was successfully treated medically with N-acetylcysteine and L-carnitine. During
recovery she again developed features of encephalopathy and had repeated convulsions associated with moderate
hypertension. The diagnosis of posterior reversible encephalopathy syndrome was made on clinical and radiological
grounds and she showed a gradual improvement with control of blood pressure.
Conclusions: This report adds to the evidence behind treatment of valproate-induced acute liver failure with
N-acetylcysteine and L-carnitine and illustrates a rare but interesting association between acute liver failure
and posterior reversible encephalopathy syndrome.
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Hepatotoxicity is a well-recognized complication of so-
dium valproate therapy and when progressed to acute
liver failure (ALF) carries a lethal prognosis with a
transplant-free survival below 25% [1]. Medical treat-
ment of ALF is currently imperfect even in the best of
centers and evidence-based options are limited [2].
Posterior reversible encephalopathy syndrome (PRES)
is an extremely rare radiological diagnosis especially in
children. We report a pediatric patient with valproate-
induced ALF successfully treated with N-acetylcysteine
(NAC) and L-carnitine who developed PRES during
recovery.
Case presentation
A 6-year-old Sri Lankan girl who was on sodium valproate
20mg/kg per day for 3 weeks for complex partial seizures
presented with fever, anorexia and vomiting of 2 days’* Correspondence: sachithmetta@yahoo.com
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distribution, and reproduction in any mediumduration. She was previously well except for the seizures
and was developing normally. She weighed 27kg (97th
centile), had a generalized erythematous rash and mild
hepatomegaly. The rest of the physical examination was
normal. Full blood count and liver function tests done on
admission were normal (Table 1).
She continued to be ill and have high fever without a
focus for the next 7 days. She developed cracking of the
lips and her liver enlargement was progressive to be
palpable 6cm below the costal margin. She was normo-
tensive, conscious and rational. The results of investiga-
tion done on day 7 after admission revealed a rapid rise
in hepatic transaminases (Table 1). Erythrocyte sedimen-
tation rate was 15mm/hour and C-reactive protein was
12mg/dL. Renal function tests, blood sugar and blood
pH were normal. An ultrasound scan of her abdomen
revealed hepatomegaly with thickened gallbladder.
Valproate-induced hepatotoxicity was suspected and
the drug was discontinued immediately. The patient was
started on NAC infusion. Despite treatment with NAC,
she deteriorated over the next 24 hours and progressed
to hepatic encephalopathy and needed elective intub-
ation and ventilation in an Intensive Care Unit (ICU).ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.













Hemoglobin (g/dL) 13.0 13.2 12.8 10.0
White cell count (/L) 7.6 × 109 28.0 × 109 33 × 109 19 × 109
Neutrophils (%) 50% 44% 38% 40%
Lymphocytes (%) 48% 46% 48% 48%
Eosinophils (%) 2% 10% 14% 12%
Platelet count (/L) 157 × 109 411 × 109 409 × 109 544 × 109
Alanine aminotransferase (U/L) 18 625 1026 702
Aspartate aminotransferase (U/L) 43 1199 2768 1024
Serum bilirubin (g/dL) 0.5 13.0 9.9
Serum albumin (g/dL) 2.9 2.3 3.2
Serum globulin (g/dL) 1.9 2.5 3.6
International normalized ratio 1.48 3.25 1.3
Serum alkaline phosphatase (U/L) 1839 1272 1043
Figure 1 Contrast-enhanced computed tomography scan of
brain showing bilateral symmetrical paramedian hypodensities
involving cortical and subcortical white matter seen in
posterior parietal regions suggestive of posterior reversible
encephalopathy syndrome.
Mettananda et al. Journal of Medical Case Reports 2013, 7:144 Page 2 of 4
http://www.jmedicalcasereports.com/content/7/1/144She was deeply comatosed over the next 2 days with se-
vere encephalopathy. Hepatic transaminases continued
to rise, serum bilirubin increased to 13mg/dL and inter-
national normalized ratio rose to 3.25 (Table 1). During
this period NAC infusion was continued, supportive
therapy with intravenous hydration, fresh frozen plasma,
intravenous mannitol, broad spectrum antibiotics, phos-
phate enema, lactulose and routine monitoring were con-
tinued. Intravenous L-carnitine 100mg/kg loading dose
was given and continued at 50mg/kg twice a day for 2 days.
Due to the limited availability of the drug in the country
the treatment with L-carnitine was continued with its oral
preparation thereafter. After 4 days in the ICU she showed
improvement in her level of consciousness and the liver
enzymes started to drop. Two days later she was extubated
and had a Glasgow Coma Scale (GCS) of 15.
On the following day her blood pressure increased
abruptly to 140/100mmHg (above the 99th centile). She de-
veloped several multifocal clonic convulsions with alterna-
ting involvement of both upper limbs and her consciousness
level deteriorated again. She was unable to complain of
headache or visual disturbances. The results of biochemical
investigations including electrolytes, calcium, and sugar were
normal. Liver transaminases continued to drop (Table 1).
Due to recurrent convulsions a contrast-enhanced com-
puted tomography (CT) scan of her brain was performed.
The CT scan showed multiple hypodense areas involving
cortical and subcortical white matter in bilateral posterior
parietal regions (Figure 1). PRES was diagnosed and her
blood pressure was controlled using intravenous hydra-
lazine and magnesium sulfate. Seizures were managed
with intravenous midazolam. She was reintubated, venti-
lated and NAC and L-carnitine were omitted.Blood pressure normalized with therapy, GCS improved
rapidly and she was extubated after 2 days of ventilation.
She did not develop further convulsions and was
discharged home after 5 days. During review after 2 weeks
and monthly reviews thereafter she continued to be free of
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sive and had normal liver functions even after 6 months.
Discussion
Drug-induced liver injury (DILI) is a diagnostic and
therapeutic challenge [3]. The true incidence of DILI re-
mains unknown but an incidence of up to 14 cases per
100,000 has been reported [1-3]. DILI is due to predic-
table dose-dependent toxicity or idiosyncratic reactions
as in the case with sodium valproate. A minority (25% to
30%) of patients with DILI present with symptoms sug-
gestive of immunoallergic drug reaction with fever, rash
and eosinophilia [3]. Our patient had all these features
and probably had this type of reaction to valproate.
ALF in children is difficult to manage and carries a high
risk of mortality even in countries where liver transplan-
tation is widely available. Mortality from ALF due to drugs
(excluding paracetamol) is more than 75% [1]. In Sri Lanka,
only a few cadaveric liver transplants have been performed
and experience is limited on live-related or pediatric trans-
plant. Hence our options were restricted to meticulous sup-
portive care and medical treatment modalities.
NAC has a proven benefit in the treatment of ALF due
to paracetamol overdose [2]. In a prospective double blind
trial in the United States of America intravenous NAC in-
fusion for 72 hours improved the transplant-free survival
in patients with early stage non-paracetamol-related ALF
[4]. The effectiveness of NAC is attributed to anti-oxidant
and anti-inflammatory mechanisms as well as to its action
on modulating the intrinsic pathway of apoptosis [1-5].
Our patient received NAC early in the disease process
before developing encephalopathy. Although it could
not prevent progression to encephalopathy it probably
helped in ultimate survival without transplantation or
long-term sequel.
In a few previous case reports intravenous L-carnitine
had beneficial effects in management of acute poisoning,
idiosyncratic hepatotoxicity and hyperammonemic en-
cephalopathy due to valproate [6-10]. It has been hy-
pothesized that valproate therapy may induce a carnitine
deficiency [10] and some data suggest valproate-induced
hepatotoxicity may be promoted by pre-existing carni-
tine deficiency or by deficiency induced by valproate per
se [6]. There was no definite evidence for a suitable dose
of L-carnitine; hence we used a loading dose of 100mg/
kg followed by 50mg/kg twice a day.
The most striking feature illustrated in this case report
is the development of PRES during recovery which has
not been reported previously to the best of our knowledge.
PRES is a poorly understood entity characterized by head-
ache, seizures, encephalopathy, visual disturbances and
radiologic findings of focal reversible vasogenic edema
[11]. In this patient PRES was diagnosed due to the re-
appearance of seizures and features of encephalopathydespite improvement in liver transaminase levels and the
characteristic features in the contrast-enhanced CT scan.
Recognized causes of PRES include acute hyperten-
sion, pre-eclampsia, renal disease, sepsis, autoimmune
disease and exposure to immunosuppressants [11]. It
has been reported in association with glomerulonephritis
[12], treatment of leukemia [13], liver transplantation
[14], steroid treatment [15] and cyclical vomiting [16]. A
recent case report described an association between
PRES and chronic liver failure and the authors suggested
hyperammonemia as a possible etiological factor [17].
The causal relationship between PRES and hypertension
is controversial; many believe hypertension to be a cause
but there is some evidence to suggest that it is a second-
ary effect [13]. In our patient an acute rise in blood pres-
sure was detected with the onset of other features of
PRES and it was transient. Notably we do not have an al-
ternative explanation for the hypertension. This makes
us believe it to be a feature or a secondary effect of PRES
rather than the cause. However, the symptoms and signs
of PRES disappeared with treatment of hypertension as is
the case in many other reports [12,18]. This indicates
that hypertension may have an effect in the progression
of the disease.
Another explanation would be that PRES is a variant of
cerebral edema which is a common complication of ALF.
However, in this patient the clinical picture of PRES deve-
loped during recovery from ALF. Further, both NAC and
L-carnitine need to be considered a cause or causes of
PRES although it has not been reported previously, which
may be due to the infrequent usage of both drugs. Both
drugs were omitted after development of PRES.
Conclusion
In conclusion this report adds to the evidence behind treat-
ment of valproate-induced ALF with NAC and L-carnitine
and illustrates a rare association between ALF and PRES.
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